blu-263
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 6, 2021 (NCT04910685)
Timeline
Indications
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05609942 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2022 | Blueprint Medicines Corporation |
| NCT04910685 | Phase 2/Phase 3 (Phase 3) | Oct 6, 2021 | Blueprint Medicines Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blueprint Medicines Corporation | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1